MHLW To Review Shionogi’s Idiopathic Pulmonary Fibrosis Drug
This article was originally published in PharmAsia News
The first section on drugs of the Pharmaceutical Affairs and Food Sanitation Council at the Ministry of Health, Labor and Welfare will review Shionogi's pirfenidone for the treatment of idiopathic pulmonary fibrosis. The Phase III trial conducted this year at Shinagawa Prefecture Cardiovascular and Respiratory Center showed a delay of symptom progression compared to placebo. Designated as an intractable disease in Japan, IPF currently has no thorough treatment. (Click here for more - Japanese language
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.